There is a growing awareness that complement plays an integral role in human physiology
and disease, transcending its traditional perception as an accessory system for pathogen …

Therapeutic modulation of the human complement system is considered a promising
approach for treating a number of pathological conditions. Owing to its central position in the …

Undesired complement activation is a major cause of tissue injury in various pathological
conditions and contributes to several immune complex diseases. Compstatin, a 13-residue …

We present new findings in our drug discovery effort to develop an anticomplement
therapeutic. We have designed several active analogues of compstatin by altering its amino …

In the year 2003 there was a 17% increase in the number of publications citing work
performed using optical biosensor technology compared with the previous year. We collated …

Compstatin is a 13-residue disulfide-bridged peptide that inhibits a key step in the activation
of the human complement system. Compstatin and its derivatives have shown great promise …

The present invention features the use of compstatin and complement inhibiting analogs
thereof for treating and/or preventing age related macular degeneration and other conditions …

In some aspects, the present invention provides methods of treating a subject in need of
treatment for neuropathic pain, the method comprising administering a compStatin analog to …

Compstatin is a 13-residue cyclic peptide that has the ability to inhibit the cleavage of C3 to
C3a and C3b. The effects of targeting C3 cleavage are threefold, and result in hindrance …

We report the computational and rational design of new generations of potential peptide‐
based inhibitors of the complement protein C3 from the compstatin family. The binding …